Updates are available Correction dated 2022-09-16
Click to view Correction: https://doi.org/10.1038/s41398-022-02168-6
-
Authors
Pu, Yaoyu
Zhang, Qiuping
Tang, Zhigang
Lu, Chenyang
Wu, Liang
Zhong, Yutong
Chen, Yuehong
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
Luo, Yubin
Liu, Yi
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21H00184, 21H05612)
National Natural Science Foundation of China (82101616, 81973540)
- License Information
-
More Information
Article History
Received: 13 January 2022
Revised: 19 May 2022
Accepted: 25 May 2022
First Online: 1 June 2022
Change Date: 16 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-022-02168-6
Competing interests
: Dr. K. H. is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. K. H. has also received speakers’ honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. The other authors declare no competing interests.
